DMT and Major Depressive Disorder
At the PSYCH Symposium on 11 May, industry leaders will connect and collaborate to expedite access to psychedelic-based healthcare across Europe.
Small Pharma is conducting the first ever clinical trial with DMT therapy to treat Major Depressive Disorder (MDD), with Chief Medical and Scientific Officer Dr Carol Routledge speaking at the event.
More than 280 million people suffer from depression worldwide, and Major Depressive Disorder costs European economies over US$130 billion each year.
As a result, medical innovation could have dramatic benefits both socially and economically.READ MORE